GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial
Prevention Rate Still Undisclosed
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.
You may also be interested in...
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.
The company has not revealed any details of the potential safety issue that led to the decision.
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.